A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma

To determine the outcome of patients with metastatic malignant melanoma (MMM) treated with palliative whole brain radiotherapy (WBRT) and to identify factors that predict treatment outcome to assist future trial design, a retrospective study was performed on patients with MMM who received WBRT at th...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2004-08, Vol.91 (5), p.829-833
Main Authors: Morris, S L, Low, S H, A'Hern, R P, Eisen, T G, Gore, M E, Nutting, C M, Harrington, K J
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Brain Neoplasms - mortality
Brain Neoplasms - radiotherapy
Brain Neoplasms - secondary
Brain research
Cancer Research
Clinical
Dermatology
Drug Resistance
Epidemiology
Female
Humans
Karnofsky Performance Status
Male
Medical prognosis
Medical research
Medical sciences
Melanoma
Melanoma - mortality
Melanoma - radiotherapy
Melanoma - secondary
Metastasis
Middle Aged
Molecular Medicine
Multivariate analysis
Oncology
Palliative Care
Patients
Prognosis
Prospective Studies
Radiation therapy
Skin cancer
Surgery
Survival Analysis
Treatment Outcome
Tumors
Tumors of the skin and soft tissue. Premalignant lesions
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To determine the outcome of patients with metastatic malignant melanoma (MMM) treated with palliative whole brain radiotherapy (WBRT) and to identify factors that predict treatment outcome to assist future trial design, a retrospective study was performed on patients with MMM who received WBRT at the Royal Marsden Hospital between 1998 and 2003. Data regarding patient factors, tumour factors and survival were collected. A total of 112 patients were identified and full data were available for 102 patients. The median age was 53 years (range 25–81 years), 66.7% were male and 33.3% female. The median dose prescribed was 20 Gy in five fractions as a mid-plane dose. The median survival after WBRT for the whole group was 51 days (range 3–1386). In an attempt to define prognostic groups, we used the validated RTOG recursive partitioning analysis (RPA) classification for brain metastasis (class 1: Karnofsky Performance Score (KPS) ⩾70%, age
ISSN:0007-0920
1532-1827
DOI:10.1038/sj.bjc.6602018